ArticleScientific reports2026
Analysis of capivasertib via ion-pairing with erythrocin B as a spectrofluorometric probe.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel, eco-friendly spectrofluorimetric method has been developed for the sensitive determination of capivasertib, based on resonance Rayleigh scattering enhancement. Unlike previously reported methods, this approach utilizes erythrosine B as a safer ion-pairing reagent in an acidic aqueous medium, eliminating the need for organic solvents or complex extraction steps. The interaction between capivasertib and erythrosine B leads to a stable ion-pair complex, producing a strong Rayleigh scattering signal measurable at λex530/λem550 nm. The method demonstrated excellent linearity over the range of 20-2000 ng mL⁻¹, with a detection limit of 5.61 ng mL⁻¹ and a quantification limit of 17 ng mL⁻¹. All analytical parameters were optimized and validated according to ICH guidelines. To holistically substantiate sustainability, the method's environmental and practical profiles were appraised using all contemporary greenness/whiteness/applicability metrics employed in this work: Analytical Eco-Scale (ESA), NEMI pictogram, GAPI, AGREE, and AGREE-prep for sample-preparation greenness; the White Analytical Chemistry RGB12 model (whiteness); and the Blue Applicability Grade Index (BAGI) (blueness/applicability). This work introduces a greener, simpler, and more accessible alternative for capivasertib analysis, with potential applications in pharmaceutical quality control and routine laboratory testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.